State-level disparities in cervical cancer prevention and outcomes in the United States: a modeling study.

Abstract

Background: Despite human papillomavirus (HPV) vaccines' availability for over a decade, coverage across the United States varies. Although some states have tried to increase HPV vaccination coverage, most model-based analyses focus on national impacts. We evaluated hypothetical changes in HPV vaccination coverage at the national and state levels for California, New York, and Texas using a mathematical model.

Methods: We developed a new mathematical model of HPV transmission and cervical cancer, creating national- and state-level models, incorporating country- and state-specific vaccination coverage and cervical cancer incidence and mortality. We quantified the national- and state-level impact of increasing HPV vaccination coverage to 80% by 2025 or 2030 on cervical cancer outcomes and the time to elimination defined as less than 4 per 100 000 women.

Results: Increasing vaccination coverage to 80% in Texas over 10 years could reduce cervical cancer incidence by 50.9% (95% credible interval [CrI] = 46.6%-56.1%) by 2100, from 1.58 (CrI = 1.19-2.09) to 0.78 (CrI = 0.57-1.02) per 100 000 women. Similarly, New York could see a 27.3% (CrI = 23.9%-31.5%) reduction from 1.43 (CrI = 0.93-2.07) to 1.04 (CrI = 0.66-1.53) per 100 000 women, and California a 24.4% (CrI = 20.0%-30.0%) reduction from 1.01 (CrI = 0.66-1.44) to 0.76 (CrI = 0.50-1.09) per 100 000 women. Achieving 80% coverage in 5 years will provide slightly larger and sooner reductions. If the vaccination coverage levels in 2019 continue, cervical cancer elimination could occur nationally by 2051 (CrI = 2034-2064), but state timelines may vary by decades.

Conclusion: Targeting an HPV vaccination coverage of 80% by 2030 will disproportionately benefit states with low coverage and higher cervical cancer incidence. Geographically focused analyses can better inform priorities.